Skip to main content

Table 2 Stepwise logistic regression of the duration of polypharmacy and ARF

From: A population-based study on the association between acute renal failure (ARF) and the duration of polypharmacy

  β ˆ SE( β ˆ ) Adjusted odds ratio p-value
Duration of polypharmacy: Less than 30 days*
 31- 90 days 0.28 0.03 1.33 <0.001
 91 – 180 days 0.50 0.03 1.65 <0.001
 Over 181 days 0.55 0.03 1.74 <0.001
Gender:Female*     
Male 0.28 0.02 1.32 <0.001
Age:0-18 years old *     
 19-64 years old 1.86 0.08 6.40 <0.001
 65-79 years old 2.19 0.08 8.93 <0.001
 Over 80 years old 2.67 0.08 14.46 <0.001
ICUs 1.48 0.02 4.37 <0.001
Comorbidity     
ASHD −0.23 0.02 0.80 <0.001
CHF 0.67 0.03 1.95 <0.001
CVA/TIA 0.21 0.02 1.24 <0.001
PVD 0.14 0.04 1.15 0.001
Other cardiac 0.08 0.03 1.09 0.006
COPD −0.10 0.02 0.91 <0.001
GI 0.30 0.02 1.36 <0.001
Liver disease 0.15 0.02 1.16 <0.001
 Cancer 0.65 0.02 1.92 <0.001
 Diabetes 0.46 0.02 1.58 <0.001
Site of operation     
Nervous system −0.82 0.07 0.44 <0.001
Endocrine system −2.25 0.26 0.11 <0.001
Nose, mouth and pharynx −0.58 0.14 0.56 <0.001
Respiratory system −0.30 0.03 0.75 <0.001
Cardiovascular system 0.38 0.02 1.47 <0.001
Digestive system 0.26 0.02 1.30 <0.001
Urinary system −0.21 0.03 0.81 <0.001
Male genital organs −1.38 0.54 0.25 0.010
Female genital organs −2.63 1.01 0.07 0.009
Musculoskeletal system −0.15 0.06 0.86 0.007
Integumentary system 0.11 0.05 1.12 0.039
Miscellaneous diagnostic and therapeutic procedures 0.35 0.02 1.42 <0.001
  1. * reference group.